Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccines
Intranasal vaccine is designed to curb virus transmission and confer protective immunity
Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the company has entered into an exclusive license agreement with Washington University in St. Louis, MO for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered COVID-19 vaccine in the United States, Europe, and Japan. This vaccine is already authorized for emergency use in India and is an important addition to Ocugen’s COVID-19 vaccine portfolio.
https://finance.yahoo.com/news/ocugen-announces-agreement-washington-university-103000226.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.